The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Open accessAbstract
An engineered cancer immunotherapy using a collagen-binding domain enhances efficacy and reduces adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Importantly, combination treatment with CPI and IL-2 resulted in complete elimination of tumors in a considerable number of animals (9 of 13) bearing orthotopic breast cancer [137].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“immune checkpoint inhibitors (antibodies) including anti-CTLA4 and anti-PD-L1 plus IL-2 were conjugated to the collagen-binding domain of the blood protein von willebrand factor (VWF) A3 domain to reduce side effects.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This formulation allowed drug targets to bind to the tumor stroma to exert their effects locally and gained a promising efficacy and safety profile compared to the unconjugated molecules tested in several mouse models.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Danhier, F., Féron, O., & Véronique Préat, A. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,891
Cited by
Sorted by citations
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Importantly, combination treatment with CPI and IL-2 resulted in complete elimination of tumors in a considerable number of animals (9 of 13) bearing orthotopic breast cancer [137].”
BackgroundComprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 691
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics
Prakash, J., & Shaked, Y. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0002 · Cited by 416
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 230
Self-citationImmune Modulatory Properties of Collagen in Cancer
Rømer, A. M. A., Thorseth, M., & Madsen, D. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791453 · Cited by 237
Engineering cytokine therapeutics
Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T. J., Spangler, J. B., de Greef, T. F. A., et al. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00030-y · Cited by 234
Natural killer cells: a promising immunotherapy for cancer
Chu, J., Gao, F., Yan, M., Zhao, S., Yan, Z., Shi, B., & Liu, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03437-0 · Cited by 194
Kirchhammer, N., Trefny, M. P., der Maur, P. A., Laubli, H. P., & Zippelius, A. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3605 · Cited by 182
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
Wang, F., Xu, D., Su, H., Zhang, W., Sun, X., Monroe, M. K., Chakroun, R. W., Wang, Z., Dai, W., Oh, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz8985 · Cited by 152
Bhatia, V., Kamat, N. V., Pariva, T. E., Wu, L., Tsao, A., Sasaki, K., Sun, H., Javier, G., Nutt, W. S., Coleman, I. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37874-2 · Cited by 138
Self-citationEngineering interferons and interleukins for cancer immunotherapy
Holder, P. G., Lim, S. A., Huang, C., Sharma, P. A., Dagdas, Y. S., Bulutoglu, B., & Sockolosky, J. T. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114112 · Cited by 130
Williford, J., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 125
Self-citationVon Willebrand factor and cancer; metastasis and coagulopathies
Patmore, S., Dhami, S. P. S., & O’Sullivan, J. M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14976 · Cited by 123
Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Pires, I. S., Hammond, P. T., & Irvine, D. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100035 · Cited by 116
Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy
Jiang, C., Chen, K., Liu, A., Huang, H., Fan, Y.-N., Zhao, D., Ye, Q., Zhang, H., Xu, C., Shen, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21497-6 · Cited by 112
Akkın, S., Varan, G., & Bilensoy, E. (2021) · Molecules · doi:10.3390/molecules26113382 · Cited by 104
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 102
Mansurov, A., Hosseinchi, P., Chang, K., Lauterbach, A. L., Gray, L. T., Alpar, A. T., Budina, E., Slezak, A. J., Kang, S., Cao, S., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00888-0 · Cited by 104
Self-citationCollagen biology making inroads into prognosis and treatment of cancer progression and metastasis
Cavaco, A. C. M., Dâmaso, S., Casimiro, S., & Costa, L. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09888-5 · Cited by 104
Multiple roles for basement membrane proteins in cancer progression and EMT
Banerjee, S., Lo, W., Majumder, P., Roy, D., Ghorai, M., Shaikh, N. K., Kant, N., Shekhawat, M. S., Gadekar, V. S., Ghosh, S., et al. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151220 · Cited by 96
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
Liu, K., Cui, J., Zhan, Y., Ouyang, Q., Lu, Q., Yang, D., Li, X., & Yin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01561-5 · Cited by 100
Shen, X., Pan, D., Gong, Q., Gu, Z., & Luo, K. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.017 · Cited by 96
Wang, S., Li, Y., Xu, C., Dong, J., & Wei, J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008431 · Cited by 89
Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy
Sasaki, K., Ishihara, J., Ishihara, A., Miura, R., Mansurov, A., Fukunaga, K., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aaw6081 · Cited by 82
Self-citationMaximizing response to intratumoral immunotherapy in mice by tuning local retention
Momin, N., Palmeri, J. R., Lutz, E. A., Jailkhani, N., Mak, H. H., Tabet, A., Chinn, M. M., Kang, B. H., Spanoudaki, V. C., Hynes, R. O., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27390-6 · Cited by 81
Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?
He, Y., Liu, T., Dai, S., Xu, Z., Wang, L., & Luo, F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.739161 · Cited by 85
Liu, H., Shi, Y., & Qian, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.012 · Cited by 78
Wang, F., Huang, Q., Su, H., Sun, M., Wang, Z., Chen, Z., Zheng, M., Chakroun, R. W., Monroe, M. K., Chen, D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204621120 · Cited by 76
Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix
Flies, D. B., Langermann, S., Jensen, C., Karsdal, M. A., & Willumsen, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199513 · Cited by 79
Cytokine engineering for targeted cancer immunotherapy
Bonati, L., & Tang, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.01.007 · Cited by 76
Wang, M., Yan, D., Wang, M., Wu, Q., Song, R., Huang, Y., Rao, J., Wang, D., Zhou, F., & Tang, B. Z. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202205371 · Cited by 74
Nanocarriers for cancer nano-immunotherapy
Rana, I., Oh, J., Baig, J., Moon, J. H., Son, S., & Nam, J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01241-3 · Cited by 76
Targeted Drug Delivery via the Use of ECM-Mimetic Materials
Hwang, J., Sullivan, M. O., & Kiick, K. L. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00069 · Cited by 76
Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy
Strasenburg, W., Jóźwicki, J., Durślewicz, J., Kuffel, B., Parol‐Kulczyk, M., Kowalewski, A., Grzanka, D., Drewa, T. A., & Adamowicz, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909767 · Cited by 73
Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement
Chin, A. L., Jiang, S., Jang, E., Niu, L., Li, L., Jia, X., & Tong, R. (2021) · Nature Communications · doi:10.1038/s41467-021-25391-z · Cited by 71
Hydroxyethyl starch based smart nanomedicine
Wang, H., Hu, H., Yang, H., & Li, Z. (2021) · RSC Advances · doi:10.1039/d0ra09663f · Cited by 69
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy
Lombaerde, E. D., Wever, O. D., & Geest, B. G. D. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188526 · Cited by 69
Targeting Tumors Using Peptides
Scodeller, P., & Asciutto, E. K. (2020) · Molecules · doi:10.3390/molecules25040808 · Cited by 65
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 72
Katsumata, K., Ishihara, J., Mansurov, A., Ishihara, A., Raczy, M. M., Yuba, E., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1971 · Cited by 62
Self-citationProtease-controlled secretion and display of intercellular signals
Vlahos, A. E., Kang, J., Aldrete, C. A., Zhu, R., Chong, L. S., Elowitz, M. B., & Gao, X. J. (2022) · Nature Communications · doi:10.1038/s41467-022-28623-y · Cited by 64
Present Scenario of Bioconjugates in Cancer Therapy: A Review
Wadhawan, A., Chatterjee, M., & Singh, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215243 · Cited by 54
Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
Kim, J., Lee, K.-J., & Lee, S. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.257 · Cited by 52
Self-citationWang, F., Su, H., Wang, Z., Anderson, C. F., Sun, X., Wang, H., Laffont, P., Hanes, J. S., & Cui, H. (2023) · ACS Nano · doi:10.1021/acsnano.3c01748 · Cited by 51
Polymeric materials for immune engineering: Molecular interaction to biomaterial design
Soni, S. S., & Rodell, C. B. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.016 · Cited by 52
Strategies for Efficient Targeting of Tumor Collagen for Cancer Therapy
Baldari, S., Modugno, F. D., Nisticò, P., & Toietta, G. (2022) · Cancers · doi:10.3390/cancers14194706 · Cited by 53
Wang, Y., Li, W., Li, Z., Mo, F., Chen, Y., Iida, M., Wheeler, D. L., & Hu, Q. (2023) · Science Advances · doi:10.1126/sciadv.adf6854 · Cited by 52
Qu, Y., Dunn, Z. S., Chen, X., MacMullan, M. A., Cinay, G. E., Wang, H.-Y., Liu, J., Hu, F., & Wang, P. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.050 · Cited by 47
Biomaterials-Mediated Engineering of the Immune System
Backlund, C. M., Jalili‐Firoozinezhad, S., Kim, B., & Irvine, D. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-040259 · Cited by 52
Luo, J., Zhang, Z., Zeng, Y., Dong, Y., & Ma, L. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.117964 · Cited by 47
Understanding the matrix: collagen modifications in tumors and their implications for immunotherapy
Borst, R., Meyaard, L., & Ramos, M. I. P. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05199-3 · Cited by 53
Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma
Morrell, M. B. G., Alvarez‐Florez, C., Zhang, A., Kleinerman, E. S., Savage, H., Marmonti, E., Park, M., Shaw, A., & Schadler, K. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27835 · Cited by 52
New opportunities for immunomodulation of the tumour microenvironment using chemical tools
Su, J., Li, W., & Li, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00486k · Cited by 44
Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Rawla, P., Barsouk, A. A., Hadjinicolaou, A. V., & Barsouk, A. (2019) · Medical Sciences · doi:10.3390/medsci7080083 · Cited by 46
Improving safety of cancer immunotherapy via delivery technology
Hu, D., Zhang, W., Tang, J., Zhou, Z., Liu, X., & Shen, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120407 · Cited by 43
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy
Uricoli, B., Birnbaum, L. A., Do, P., Kelvin, J., Jain, J., Costanza, E., Chyong, A., Porter, C. C., Rafiq, S., & Dreaden, E. C. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002214 · Cited by 43
Switchable immune modulator for tumor-specific activation of anticancer immunity
Zhao, Y., Xie, Y., Herck, S. V., Nassiri, S., Gao, M., Guo, Y., & Tang, L. (2021) · Science Advances · doi:10.1126/sciadv.abg7291 · Cited by 42
Wang, F., Su, H., Xu, D., Monroe, M. K., Anderson, C. F., Zhang, W., Oh, R., Wang, Z., Sun, X., Wang, H., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121182 · Cited by 42
Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
Henze, J., Tacke, F., Hardt, O., Alves, F., & Rawashdeh, W. A. (2020) · Cancers · doi:10.3390/cancers12061389 · Cited by 39
Manna, S., Maiti, S., Shen, J., Weiss, A. M., Mulder, E. J., Du, W., & Esser-Kahn, A. P. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122062 · Cited by 39
Battistella, C., Liang, Y., & Gianneschi, N. C. (2021) · Advanced Materials · doi:10.1002/adma.202007504 · Cited by 38
Harnessing molecular recognition for localized drug delivery
Liu, R., Zuo, R., & Hudalla, G. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.008 · Cited by 37
Willumsen, N., Jensen, C., Green, G. A., Nissen, N. I., Neely, J., Nelson, D. M., Pedersen, R. S., Frederiksen, P., Chen, I. M., Boisen, M. K., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04226-0 · Cited by 37
Closset, L., Gultekin, O., Salehi, S., Sarhan, D., Lehti, K., & Gonzalez‐Molina, J. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.07.003 · Cited by 36
Therapeutic Development of Immune Checkpoint Inhibitors
Wang, J., Yang, T., & Xu, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_23 · Cited by 34
The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer
Colonne, C. K., Favaloro, E. J., & Pasalic, L. (2022) · Healthcare · doi:10.3390/healthcare10030557 · Cited by 33
Nano drug delivery systems: a promising approach to scar prevention and treatment
Ding, J.-Y., Sun, L., Zhu, Z.-H., Wu, X., Xu, X., & Xiang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02037-4 · Cited by 35
Kang, S., Mansurov, A., Kurtanich, T. R., Chun, H. R., Slezak, A. J., Volpatti, L. R., Chang, K., Wang, T., Alpar, A. T., Refvik, K. C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh9879 · Cited by 34
Self-citationEngineering Targeting Materials for Therapeutic Cancer Vaccines
Briquez, P. S., Hauert, S., de Titta, A., Gray, L. T., Alpar, A. T., Swartz, M. A., & Hubbell, J. A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00019 · Cited by 32
Self-citationOvercoming biological barriers to improve solid tumor immunotherapy
Ukidve, A., Cu, K., Kumbhojkar, N., Lahann, J., & Mitragotri, S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00923-8 · Cited by 33
Type XX Collagen Is Elevated in Circulation of Patients with Solid Tumors
Thorlacius‐Ussing, J., Jensen, C., Madsen, E. A., Nissen, N. I., Manon‐Jensen, T., Chen, I. M., Johansen, J. S., Diab, H. M. H., Jørgensen, L. N., Karsdal, M. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084144 · Cited by 32
Mu, J., Du, Y., Li, X., Yan, R., Zhong, H., Cai, M., Yu, N. H., Zhang, J., Yuan, X., Hua, X., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.138554 · Cited by 32
Qin, Y., Wang, G., Chen, L., Sun, Y., Yang, J., Piao, Y., Shen, Y., & Zhou, Z. (2023) · Advanced Materials · doi:10.1002/adma.202302292 · Cited by 31
Park, S., Oh, J. H., Park, D. J., Zhang, H., Noh, M., Kim, Y., Kim, Y.-S., Kim, H., Kim, Y., Ha, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620166 · Cited by 30
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
Li, W., Peng, A., Wu, H., Quan, Y., Li, Y., Lu, L., & Cui, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.601497 · Cited by 29
Aghlara-Fotovat, S., Nash, A., Kim, B., Krencik, R., & Omid Veiseh, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01018-0 · Cited by 29
The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance
Fromme, J. E., & Zigrino, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.864302 · Cited by 27
Liu, J., Meng, Z., Xu, T., Kuerban, K., Wang, S., Zhang, X., Fan, J., Ju, D., Tian, W., Huang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845217 · Cited by 27
Nanomedicine for Acute Brain Injuries: Insight from Decades of Cancer Nanomedicine
Kandell, R. M., Waggoner, L. E., & Kwon, E. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00287 · Cited by 27
Kandell, R. M., Kudryashev, J. A., & Kwon, E. J. (2021) · ACS Nano · doi:10.1021/acsnano.1c09064 · Cited by 26
Advancements and challenges in immunocytokines: A new arsenal against cancer
Shi, W., Liu, N., & Lu, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.024 · Cited by 25
Targeting collagen to optimize cancer immunotherapy
Wang, Y., Zhang, F., Qian, Z., Ying, J., Wu, D., Liu, L., Ning, X., Mei, J., Chen, D., & Zhang, Y. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00691-y · Cited by 28
Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers
Harrison, A. J., Du, X., von Scheidt, B., Kershaw, M. H., & Slaney, C. Y. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab016 · Cited by 24
Intratumorally anchored cytokine therapy
Wittrup, K. D., Kaufman, H. L., Schmidt, M. M., & Irvine, D. J. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2084070 · Cited by 25
Collado, J., Boland, L. K., Ahrendsen, J. T., Miska, J. M., & Lee-Chang, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336476 · Cited by 28
Immunoengineering approaches for cytokine therapy
Mansurov, A., Lauterbach, A. L., Budina, E., Alpar, A. T., Hubbell, J. A., & Ishihara, J. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00515.2020 · Cited by 23
Self-citationRemodeling the tumor dormancy ecosystem to prevent recurrence and metastasis
Liang, Y., Chen, W., Zhang, Y., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02328-2 · Cited by 29
Synthetic Tuning of Domain Stoichiometry in Nanobody–Enzyme Megamolecules
Metcalf, K. J., Kimmel, B. R., Sykora, D. J., Modica, J. A., Parker, K. A., Berens, E. B., Dai, R., Dravid, V. P., Werb, Z., & Mrksich, M. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00578 · Cited by 22
Engineering multi-specific nano-antibodies for cancer immunotherapy
Fan, Y.-N., Zhu, L., Qing, Y.-X., Ye, S.-Y., Ye, Q., Huang, X., Zhao, D., Tian, T.-Y., Li, F.-C., Yan, G.-R., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01425-5 · Cited by 21
Kang, S., Mansurov, A., Kurtanich, T. R., Chun, H. R., Slezak, A. J., Volpatti, L. R., Chang, K., Wang, T., Alpar, A. T., Refvik, K. C., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009541 · Cited by 23
Self-citationManna, S., Maiti, S., Shen, J., Du, W., & Esser-Kahn, A. P. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c01001 · Cited by 21
Overcoming the limitations of cytokines to improve cancer therapy
Trani, C. A. D., Cirella, A., Arrizabalaga, L., Fernández-Sendin, M., Bella, Á., Aranda, F., Melero, I., & Berraondo, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.05.002 · Cited by 22
Lozeau, L. D., Grosha, J., Smith, I. M., Stewart, E. J., Camesano, T. A., & Rolle, M. W. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00227 · Cited by 20
Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview
Boersma, B., Poinot, H., & Pommier, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16080974 · Cited by 19
Metadata
- Authors
- Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., Raczy, M. M., Gray, L. T., Mansurov, A., Katsumata, K., Fukayama, M., Kron, S. J., Swartz, M. A., & Hubbell, J. A.
- Affiliations
- University of Chicago (US)
- Department of Molecular Genetics and Cell Biology, University of Chicago, Chicago, IL 60637, USA.
- The University of Tokyo (JP)
- Department of Pathology, University of Tokyo, 113-8655 Tokyo, Japan.
- Corresponding author
- Ishihara, Jun
- Ishihara, Ako
- Katsumata, Kiyomitsu
- Hubbell, Jeffrey A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-04-10
- Volume
- 11
- Issue
- 487
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6541444
- OpenAlex
- W2939112943
- Cited by
- 190
- References
- 49
- Citations by year
- 2026: 20 · 2025: 16 · 2024: 20 · 2023: 30 · 2022: 34 · 2021: 35 · 2020: 23 · 2019: 12
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Cancer Institute (CA199663)
- National Institute of Biomedical Imaging and Bioengineering (EB022636)
- European Research Commission grant (Cytrix)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- cancer immunotherapy, cytokine therapy, interleukin-2, antibody-drug conjugates, breast cancer, tumor targeting, combination therapy, orthotopic tumor model
- MeSH terms
- Protein Domains, Animals, Antibodies, Neoplasm, Collagen, Cytotoxicity, Immunologic, Disease Models, Animal, Humans, Immunity, Immunotherapy, Injections, Intravenous, Interleukin-2, Melanoma, Experimental, Mice, Inbred BALB C, Mice, Inbred C57BL, Cytokines, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, CD8-Positive T-Lymphocytes, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
